Redx Pharma sees potential for RXC004 as a combination therapy
Recommended All Share Merger of Redx and Jounce Therapeutics Webcast 23 February 2023
Annual Results Presentation Webcast 20 December 2022
Lisa Anson, Jefferies Healthcare Conference Presentation 17 November 2022
Redx Pharma begins phase II trial for RXC007 in idiopathic pulmonary fibrosis
Chief Executive Officer, Lisa Anson discusses Redx’s Progress at Proactive One2One Investor Forum
Interim 2022 Results Webcast (23-June-2022)
CEO, Lisa Anson, discusses recent events here at Redx, including the IND clearance of our partnered pan-RAF inhibitor programme with Jazz Pharmaceuticals
ILD Summit Presentation: Selective Inhibition of ROCK2 – Promising Approach to Target Fibrosis 9 March 2022
Lisa Anson, Cowen Healthcare Conference Webcast 9 March 2022
Annual Results Presentation Webcast, 27 January 2022
Lisa Anson, Piper Healthcare Conference Presentation, 30 November 2021
Caroline Phillips, Wnt Conference Presentation, 18 November 2021
Lisa Anson, Jefferies Healthcare Conference Presentation, 17 November 2021
Redx Pharma R&D Day Webcast 11th October 2021
Chief Executive Officer, Lisa Anson discusses Redx’s pipeline progress
Chief Scientific Officer, Richard Armer provides a recap on lead fibrosis asset, RXC007 which has potential for development in multiple fibrotic conditions
Chief Medical Officer, Jane Robertson provides an update on progress of our lead cancer drug candidate RXC004
Interim 2021 Results webcast (07-June-2021)
Annual results presentation webcast (15-Feb-2021)
Cowen Health Care Conference Presentation (Thursday 04-March-2021 at 16:10 GMT / 11:10 EST)
CEO Lisa Anson discussed £25.5m raise to drive forward key programmes
Chief Medical Officer, Dr Andrew Saunders, provides updates on lead oncology asset RXC004
Chief Scientific Officer Richard Armer provides updates on lead fibrosis asset RXC007 which has potential for development in multiple fibrotic conditions